Targeted treatment for patients with estrogen receptor negative and progesterone receptor negative breast cancers

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9314515
APP PUB NO 20110150935A1
SERIAL NO

12989233

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Treatments for estrogen receptor and progesterone receptor negative breast cancer or estrogen receptor, progesterone receptor and c-erbB2 negative (triple negative) breast cancer are provided.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD666 THIRD AVENUE 28TH FLOOR NEW YORK NY 10017

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Caballero, Otavia L Lutherville, US 4 6
Grigoriadis, Anita London, GB 1 3
Simpson, Andrew John George Westport, US 10 15

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 19, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00